Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients

Arvind Gharbharan, Corine H GeurtsvanKessel, Carlijn C E Jordans, Marc Blaauw, Marjolein van der Klift, Robert-Jan Hassing, Marijn Smits-Zwinkels, Maaike Meertens, Ella C van den Hout, Anne Marie de Man, Ilse Hageman, Susanne Bogers, C Ellen van der Schoot, Francis Swaneveld, Adam A Anas, Casper Rokx, Bart J A Rijnders, Arvind Gharbharan, Corine H GeurtsvanKessel, Carlijn C E Jordans, Marc Blaauw, Marjolein van der Klift, Robert-Jan Hassing, Marijn Smits-Zwinkels, Maaike Meertens, Ella C van den Hout, Anne Marie de Man, Ilse Hageman, Susanne Bogers, C Ellen van der Schoot, Francis Swaneveld, Adam A Anas, Casper Rokx, Bart J A Rijnders

Abstract

Twenty-five B-cell-depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.

Trial registration: ClinicalTrials.gov NCT04375098.

Keywords: 19; 2; B; COVID; CoV; SARS; cell depletion; convalescent plasma; immunodeficiency.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Enzyme-linked immunosorbent assay (ELISA) severe acute respiratory syndrome coronavirus 2 total immunoglobulin (IgTot) optical density (OD) ratios and 50% plaque reduction neutralization test (PRNT50) titer after transfusion in 16 evaluable patients. Blue line represents the total Ig OD ratio. Red line represents the PRNT50. The vertical black line represents when the second transfusion was given.

References

    1. Sormani MP, De Rossi N, Schiavetti I, et al. . Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 2021; 89:780–9.
    1. Abani O, Abbas A, Abbas F, et al. . Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021; 397:2049–59.
    1. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. . Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun 2021; 12:267.
    1. Steenhuis M, van Mierlo G, Derksen NIL, et al. . Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. Clin Transl Immunology 2021; 10:e1285.
    1. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. . An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun 2020; 11:3436.
    1. Okba NMA, Müller MA, Li W, et al. . Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis 2020; 26:1478–88.
    1. Horby PW, Mafham M, Peto L, et al. . Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]. Posted online 16 June 2021. doi:10.1101/2021.06.15.21258542.
    1. Thompson MA, Henderson JP, Shah PK, et al. . Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 [manuscript published online ahead of print 17 June 2021]. JAMA Oncology 2021. doi:10.1001/jamaoncol.2021.1799.
    1. Hueso T, Pouderoux C, Péré H, et al. . Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood 2020; 136:2290–5.
    1. Delgado-Fernández M, García-Gemar GM, Fuentes-López A, et al. . Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency—three consecutive cases and review of the literature [manuscript published online ahead of print 11 February 2021]. Enferm Infecc Microbiol Clin (Engl Ed) 2021. doi:10.1016/j.eimc.2021.01.013.
    1. Larsen MD, de Graaf EL, Sonneveld ME, et al. . Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science 2021; 371:eabc8378.
    1. Kemp SA, Collier DA, Datir RP, et al. . SARS-CoV-2 evolution during treatment of chronic infection. Nature 2021; 592:277–82.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa